Actively Recruiting

Phase Not Applicable
Age: 18Years - 40Years
FEMALE
NCT05205317

Comparison of the Therapeutic Effects of VR and VR + Metformin in the Treatment of Cesarean Section Scar Defect

Led by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Updated on 2026-04-24

100

Participants Needed

1

Research Sites

219 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Cesarean section scar defect (CSD) is a novel recognized cause of postmenstrual abnormal uterine bleeding in women. No clinical guidelines have been issued for the management of CSD. The investigators have previously demonstrated that vaginal repair of CSD was an relative effective treatment of CSD. However, only 28.2% of the CSD patients normalized to less than 7 days of menstruation, whereas 51.2% of women had 7 to 10 days of menstruation at 6 months post vaginal repair. The previous research suggested that the occurrence of CSD may be related to the aging phenotype of the myometrium. Metformin, as a classic diabetes treatment drug, has an important position in anti-aging therapy. Therefore, the randomized study was designed to evaluate whether the application of metformin in combination with vaginal repair could achieve better clinical effects than those achieved by vaginal CSD repair alone.

CONDITIONS

Official Title

Comparison of the Therapeutic Effects of VR and VR + Metformin in the Treatment of Cesarean Section Scar Defect

Who Can Participate

Age: 18Years - 40Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients aged 18 to under 40 years
  • Diagnosed clearly with cesarean section scar defect (CSD)
  • Experiencing abnormal uterine bleeding with menstruation lasting more than 10 days
  • Thickness of remaining muscular layer of CSD less than 3 mm
  • Normal blood sugar and insulin levels
  • No serious medical problems; important organ functions within normal range
  • No uterine fibroids, endometriosis, or adenomyosis
  • No malignant tumors
  • Signed informed consent
Not Eligible

You will not qualify if you...

  • Age under 18 or over 40 years
  • Unclear diagnosis of CSD
  • Presence of malignant tumors
  • Severe medical problems such as severe liver, kidney, respiratory, heart disease, uncontrolled diabetes, epilepsy, or organ dysfunction
  • Contraindications to metformin including high creatinine levels, hypersensitivity, metabolic acidosis, or use of interacting drugs
  • Pregnancy
  • Mental illness
  • Unwillingness to follow the research plan

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, China, 200092

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here